- |||||||||| pegozafermin (BIO89-100) / 89Bio
P1/2 data, PK/PD data, Journal: Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. (Pubmed Central) - Dec 16, 2022 P1/2 Pegozafermin was generally well tolerated and associated with clinically meaningful reductions in liver fat, measures of liver function, and circulating lipids. Further evaluation of pegozafermin in individuals with NASH is warranted.
- |||||||||| pegbelfermin (BMS-986036) / BMS, BIO89-100 / 89Bio
[VIRTUAL] BIO89-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1005; Our results suggest that this BW loss is due, at least in part, to an increase in energy expenditure, resulting in a marked decrease in fat mass, including the eWAT weight, without affecting lean masses and body fluid. If these effects translate to humans, they could be beneficial in patients with metabolic diseases.
|